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INTRODUCTION 
The Guillain–Barré syndrome is one of the most common forms of 
polyneuropathy
1
.It is the commonest cause of acute flaccid quadriparesis. It can 
present with varying degrees of motor weakness, from mild weakness to total 
paralysis and respiratory failure. 
It has an unpredictable clinical course with upto 30% of patients requiring 
assisted ventilation during the course of their illness
2
. Successful management 
mandates anticipation, prompt recognition and optimal treatment of neuromuscular 
respiratory failure in GBS
3
. 
While inherently unpredictable, the course of patients with severe GBS can, 
to some extent, be predicted on the basis of clinical information like bilateral facial 
weakness, autonomic dysfunction and bulbar weakness
1,3,4
. 
Few studies have shown that measurement of baseline plasma cortisol levels 
can be helpful for early detection of patients with Guillain–Barré syndrome at risk 
for respiratory failure at least 24 hrs later
5
.  
Also electrophysiological tests are helpful for assessing risk of respiratory 
failure. However early indicators of subsequent progression to respiratory failure 
have not been clearly established. 
2 
  
This study is undertaken to find whether clinical laboratory and 
electrodiagnostic factors could help in predicting respiratory failure and hence the 
need for mechanical ventilation in GBS patients. 
These data may be helpful in the decisions regarding admission to the 
intensive care unit and preparation for elective intubation. 
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AIM AND OBJECTIVE 
AIM 
1. To assess the clinical presentation and the subsequent manifestations including 
decline in respiratory effort among 50 GBS patients admitted at Rajiv Gandhi 
Government General Hospital, Chennai. 
2. To do laboratory tests including serum cortisol and electrophysiological tests 
among 50 GBS patients admitted at Rajiv Gandhi Government General Hospital, 
Chennai. 
OBJECTIVE 
 To identify clinical, laboratory and electrophysiological features associated with 
progression to respiratory failure in GBS. 
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REVIEW OF LITERATURE 
INTRODUCTION 
Guillain–Barré syndrome (GBS) is an acute, frequently severe, and 
fulminant polyradiculoneuropathy that is autoimmune in nature
6,7
. 
GBS is the most common cause of acute or subacute generalized paralysis
2
. 
HISTORY 
The earliest description of an afebrile generalized paralysis is probably that 
of Wardrop and Ollivier, in 1834. Then in 1859, Octave Landry reported an acute, 
ascending, predominantly motor paralysis with respiratory failure, leading to 
death
8,9
. Hence GBS is sometimes called Landry’s paralysis. This was followed by 
Osler description of afebrile polyneuritis in 1892
2
. 
However this syndrome is named after the French physicians Guillain, Barré 
and Strohl, who in 1916, emphasized the main clinical features of GBS: motor 
weakness, areflexia, paresthesias with minor sensory loss, and increased protein in 
CSF without pleocytosis (albumin cytological dissociation)
10
.They reported on two 
soldiers who developed an acute paralysis associated with loss of muscle stretch 
reflexes.  
The first comprehensive account of the pathology of GBS was that of 
Haymaker and Kernohan (1949), who stressed that edema of the nerve roots was 
an important change in the early stages of the disease
11
. Asbury, Arnason, and 
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Adams (1969) established that the essential lesion, from the beginning of the 
disease, is a perivascular mononuclear inflammatory infiltration of the roots and 
nerves
12
. 
SYNONYMS 
 Acute post-infective polyradiculoneuropathy. 
 Acute infectious polyneuritis. 
 Landry–Guillain–Barré–Strohl syndrome 
 Post-infective polyneuritis 
INCIDENCE 
It occurs in all parts of the world and in all seasons, affecting children and 
adults of all ages and both sexes
2
. Males are at slightly higher risk for GBS than 
females (1.5:1)
7
, and in Western countries adults are more frequently affected than 
children
1,6
. The crude average annual incidence rate varies in different countries 
from 0.6 to 1.9 per 100,000 people
13
. The mean age of onset is around 40 but many 
series have shown a bimodal distribution with peaks in the third and sixth decades 
of life
1
. Cases are known in infants and in the very aged
2
. 
DIAGNOSTIC CRITERIA 
The diagnosis of GBS depends on clinical criteria supported by 
electrophysiological studies and CSF findings
7
.  
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Diagnostic criteria of AIDP was given by Asbury and Cornblath in 1990
8,7,6,14.
. 
I. Required for Diagnosis 
1. Progressive weakness of variable degree from mild paresis to complete paralysis 
2. Generalized hypo- or areflexia 
II.Supportive of Diagnosis 
1. Clinical Features 
a. Symptom progression: Motor weakness rapidly progresses initially but ceases by 
4 weeks. Nadir attained by 2 weeks in 50%, 3 weeks 80%, and 90% by 4 weeks. 
b. Demonstration of relative limb symmetry regarding paresis. 
c. Mild to moderate sensory signs. 
d. Frequent cranial nerve involvement: Facial (cranial nerve VII) 50% and 
typically bilateral but asymmetric; occasional involvement of cranial nerves XII, 
X, and occasionally III, IV, and VI as well as XI. 
e. Recovery typically begins 2–4 weeks following plateau phase. 
f. Autonomic dysfunction can include tachycardia, other arrhythmias, postural 
hypotension, hypertension,  other vasomotor symptoms. 
g. A preceding gastrointestinal illness (e.g., diarrhoea) or upper respiratory tract 
infection is common. 
2. Cerebrospinal Fluid Features Supporting Diagnosis 
a. Elevated or serial elevation of CSF protein. 
7 
  
b. CSF cell counts are <10 mononuclear cell/mm
3
. 
3. Electrodiagnostic Medicine Findings Supportive of Diagnosis 
a.80% of patients have evidence of NCV slowing/conduction block at some time 
during disease process. 
b. Patchy reduction in NCV attaining values less than 60% of normal. 
c. Distal motor latency increase may reach 3 times normal values. 
d. F-waves indicate proximal NCV slowing. 
e. About 15–20% of patients have normal NCV findings. 
f. No abnormalities on nerve conduction studies may be seen for several weeks. 
III. Findings Reducing Possibility of Diagnosis 
1. Asymmetric weakness 
2. Failure of bowel/bladder symptoms to resolve 
3. Severe bowel/bladder dysfunction at initiation of disease 
4. Greater than 50 mononuclear cells/mm
3
 in CSF 
5. Well-demarcated sensory level 
IV. Exclusionary Criteria 
1. Diagnosis of other causes of acute neuromuscular weakness (e.g., myasthenia 
gravis, botulism, poliomyelitis, toxic neuropathy). 
2. Abnormal CSF cytology suggesting carcinomatous invasion of the nerve roots. 
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SUBTYPES 
Griffin et al. in 1996 proposed a tentative classification of GBS subtypes 
based on the clinical picture and electrophysiological and pathological findings
15
. 
 Acute inflammatory demyelinating polyradiculoneuropathy. 
 Acute motor axonal neuropathy. 
 Acute motor sensory axonal neuropathy. 
 Miller-Fisher syndrome. 
 Acute pandysautonomia. 
 Sensory GBS. 
The most common variant is acute inflammatory demyelinating 
polyneuropathy (AIDP)
6
. There are two axonal variants, which are often clinically 
severe – the acute motor axonal neuropathy (AMAN) and acute motor sensory 
axonal neuropathy (AMSAN) subtypes
6,7
. 
A range of limited or regional GBS syndromes are also encountered. 
Notable among these are the Miller Fisher syndrome (MFS), Bickerstaff’s 
encephalitis, acute pandysautonomia, polyneuritiscranialis, pharyngeal-cervical-
brachial variant often with ptosis, oculopharyngeal weakness, bilateral facial or 
abducens weakness with distal paraesthesias. Other atypical presentations are 
areflexic paraparesis, Miller Fisher syndrome coupled with weakness of bulbar or 
arm muscles and Isolated arm weakness. 
9 
  
The Miller-Fisher syndrome (MFS), which accounts for 5% of cases, is 
characterized by ophthalmoplegia, ataxia, and areflexia
48
. Ocular signs range from 
complete ophthalmoplegia, including dilated and unreactive pupils, to external 
ophthalmoparesis with or without ptosis. Cranial nerves other than ocular motor 
nerves may be affected. Motor strength is characteristically preserved, although 
overlap with typical GBS seems to occur.  
ANTECEDENT EVENTS 
Infections 
Over half of Guillain–Barré syndrome patients experience symptoms of viral 
respiratory or gastrointestinal infections during the 1–3 weeks prior to the onset of 
neurological symptoms
16,32
. 
The neurological illness is preceded by symptoms of respiratory tract 
infection in approximately 40% and gastrointestinal infection in less than 20% in 
an English series; 8% had undergone an operation in the preceding 3 
months
16
Serological studies have implicated a wide range of infective agents. 
Cytomegalovirus (13%) and Campylobacter jejuni (in approximately 30%) are the 
most common. Epstein–Barr virus (10%), Mycoplasma pneumoniae (5%), human 
immunodeficiency virus (HIV), and childhood exanthems are also reported
16,17,18,19
. 
Others include varicella zoster virus, hepatitis A and B, and Haemophilus 
influenza, lymes disease, human herpes virus. The most common identifiable 
10 
  
bacterial organism linked to GBS and particularly its axonal forms is 
Campylobacter jejuni
7
. GBS associated with cytomegalovirus tends to occur in 
younger patients, with a high occurrence of respiratory muscle weakness, cranial 
nerve involvement, and significant sensory involvement
20
. By contrast, 
Campylobacter jejuni infection is associated with preceding diarrhoeal illness in 
70%, a pure motor disorder (AMAN) is common, and recovery can be markedly 
slow
19
. Forms of Guillain–Barré syndrome precipitated by both campylobacter and 
cytomegalovirus show delayed recovery compared to cases unassociated with these 
two infections
19
. 
Recent Immunization 
After immunization in 1976 of more than 40 million adults in the United 
States with swine influenza virus vaccine (A/New Jersey/76) more than 500 cases 
of Guillain–Barré syndrome were reported in vaccinated individuals2. Influenza 
vaccines in use from 1992 to 1994, however, resulted in only one additional case 
of GBS per million persons vaccinated, and the more recent seasonal influenza 
vaccines appear to confer a GBS risk of <1 per million
6
.No other causal 
relationship linking Guillain–Barré syndrome to vaccination with other strains of 
influenza virus has been shown. A prospective case-control study in England 
showed no significant excess of any form of vaccination during the 3 months 
preceding the Guillain–Barré syndrome18. 
11 
  
Others
 
 Systemic lupus erythematosus (SLE). 
 Lymphoma (including Hodgkin's disease).21 
 Exposure to thrombolytic agents. 
 Drugs, including streptokinase, suramin, gangliosides, and heroin. 
 Trauma and surgery. 
 After renal transplantation from a cytomegalovirus-positive donor. 
 In pharmacologically immunosuppressed patients after solid organ or bone 
marrow transplantation. 
IMMUNOPATHOGENESIS 
GBS results from immune responses to non self antigens (infectious agents, 
vaccines) that misdirect to host nerve tissue through a resemblance-of-epitope 
(molecular mimicry) mechanism
6
. It is likely that both cellular and humoral 
immune mechanisms contribute to tissue damage in AIDP
22
.The neural targets are 
likely to be glycoconjugates, specifically gangliosides. Guillain–Barré syndrome 
bears a strong histological resemblance to experimental allergic neuritis, an acute 
monophasic disorder induced by immunization of experimental animals with 
peripheral-nerve myelin proteins, particularly P2 and galactocerebroside
24
.
 
Antiganglioside antibodies, most frequently to GM1, are common in GBS (20–
50% of cases), particularly in those preceded by C. jejuni infection
6,7
. Anti-GQ1b 
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IgG antibodies are found in >90% of patients with MFS
6,7
in cases of AMAN 
antibodies against GD1a appear to have a fine specificity that favors binding to 
motor rather than sensory nerve roots, even though this ganglioside is expressed on 
both fiber types
6
.The peripheral nerves may be affected at all levels from the roots 
to distal intramuscular motor nerve endings, although the majority of the lesions 
usually occur on the ventral roots, proximal spinal nerves, and lower cranial 
nerves
7
.  
CLINICAL FEATURES 
GBS manifests as a rapidly evolving areflexic motor paralysis with or 
without sensory disturbance. The fairly symmetrical weakness of the lower limbs 
ascends proximally over hours to several days and may subsequently involve arm, 
facial, and oropharyngeal muscles, and in severe cases, respiratory muscles. 
Hyporeflexia or areflexia are the invariable features of GBS but may be absent 
early in the course of the disease
7
.Total areflexia occurs in over 80% of patients at 
some stage of the illness. The remainder usually lose their ankle jerks in 
isolation
25
. 
The proportion of patients developing respiratory failure and requiring 
assisted ventilation ranges from 12% in epidemiological series to 30% in hospital-
based series
6,7
.The need for mechanical ventilation is associated a rapid tempo of 
progression, and the presence of facial and/or bulbar weakness and a rapid decline 
13 
  
in vital capacity
3,4,6,8,26,50
. Serial measures of decline in respiratory function that 
could predict future respiratory failure included vital capacity of less than 20 
mL/kg or a decline by 30% from baseline, maximal inspiratory pressure less than 
30 cm, and maximal expiratory respiratory pressure of less than 40 cm of H2O. 
This so-called 20–30–40 rule allows patients at risk to be identified and transferred 
to an intensive care unit for even closer monitoring
8
. In a series of 200 patients, 
short disease duration, inability to lift the head from bed, and a vital capacity of 
less than 60% predicted the need for mechanical ventilation in 85% of patients 
with all three risk factors
28
. Ropper and Kehne’s established criteria for intubation, 
it includes bulbar weakness, vital capacity <15ml/kg, and pO2on room air <70mm 
Hg
52
. When respiratory assistance is needed for longer than 2 weeks, a 
tracheostomy should be performed.  
Approximately half the patients develop cranial-nerve palsies, usually in the 
wake of severe ascending limb weakness
25, 26
. Facial paresis, usually bilateral, is 
found in at least in 50% of patients
7
. Involvement of extraocular muscles and lower 
cranial nerves is seen less often. Fever and constitutional symptoms are absent at 
the onset and, if present, cast doubt on the diagnosis.  
In three-quarters of patients, the first neurological symptom is of 
paraesthesia in the toes, less often in the fingers
2
.Cutaneous sensory deficits (e.g., 
loss of pain and temperature sensation) are usually relatively mild, but functions 
14 
  
subserved by large sensory fibers, such as deep tendon reflexes and proprioception, 
are more severely affected. Sensory loss is frequently limited to the distal 
impairment of vibration sense.When sensory signs are present, they usually consist 
of impaired vibration and joint-position sensations
25
. 
Urinary retention occurs in about 15% of patients soon after the onset of 
weakness
2
, but is usually transient. Once clinical worsening stops and the patient 
reaches a plateau (almost always within 4 weeks of onset), further progression is 
unlikely. 
Autonomic dysfunction is common in the Guillain–Barré syndrome, 
occurring in over 60%
29
. Most of the clinically significant autonomic dysfunction 
occurs within the first 2–4 weeks of the illness, the peak period of paralysis7. 
It is related to either increased or decreased sympathetic-parasympathetic 
activity, resulting in orthostatic hypotension, urinary retention, gastrointestinal 
atony, iridoplegia, episodic or sustained hypertension, sinus tachycardia, 
tachyarrhythmias, anhidrosis or episodic diaphoresis, and acral vasoconstriction. 
Excessive vagal activity accounts for sudden episodes of bradycardia, heart block, 
and asystole. Serious cardiac arrhythmias with hemodynamic instability tend to be 
more frequent in patients with severe quadriparesis and respiratory failure
7
. 
Arrhythmias, cause or contribute to death in 7% patients
30,31
. 
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Plasma cortisol and catecholamines were found to be raised in patients with 
dysautonomia presenting as hypertension and tachycardia
49
.Autonomic 
dysfunction can result in electrocardiographical changes including T-wave 
abnormalities, ST-segment depression, QRS widening, QT prolongation, and 
various forms of heart block
7
. 
Pain in the neck, shoulder, back, or diffusely over the spine is also common 
in the early stages of GBS, occurring in 50% of patients
6
. Interscapular or low back 
pain with radiation into the legs is most common
7
. 
Other pains in GBS include dysesthetic pain in the extremities as a 
manifestation of sensory nerve fiber involvement and a deep aching pain may be 
present in weakened muscles. These pains are self-limited and often respond to 
standard analgesics. 
Papilloedema occasionally develops. If so, it is sometimes associated with 
headache and raised spinal fluid pressure and tends to occur after a delay of some 
weeks
25,33
. Optic neuritis and pyramidal tract signs are other rare manifestations 
which may point to a mild associated acute disseminated encephalomyelitis 
34
. 
Recurrent Guillain–Barré syndrome occurs in up to 3%, often after an 
interval of many years
26
. 
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LABORATORY STUDIES 
CSF findings are distinctive, consisting of an elevated CSF protein level [1–
10 g/L (100–1000 mg/dL)] without accompanying pleocytosis6.In the first week of 
neurological symptoms the CSF protein may be normal but then becomes elevated 
on subsequent examinations. In approximately 10% of cases, the CSF protein 
remains normal throughout the illness
7
. 
A transient increase in the CSF white cell count (10–100/µL) occurs on 
occasion in otherwise typical GBS; however, a sustained CSF pleocytosis suggests 
an alternative diagnosis (viral myelitis) or a concurrent diagnosis such as 
unrecognized HIV infection, leukemia or lymphoma with infiltration of nerves, or 
neurosarcoidosis
6
. 
Mild transient elevations in liver enzymes without obvious cause are found 
in approximately one third of patients. Hyponatremia is seen most frequently in 
ventilated patients because of inappropriate secretion of antidiuretic hormone. 
Deposition of immune complexes may rarely lead to glomerulonephritis and result 
in microscopic haematuria and proteinuria
7
. 
Elevated serum antibodies to Mycoplasma, CMV, or C. jejuni can pinpoint 
the preceding infection. Preceding C. jejuni infection has been linked to axonal 
variants, worse outcome, and high titers of anti-GM1, anti-GD1b, anti-GD1a, and 
17 
  
anti-GalNAc-GD1a ganglioside antibodies of the IgG class
37
. Elevated anti-GQ1b 
ganglioside antibodies are consistently found in MFS.  
ELECTRODIAGNOSTIC STUDIES 
Abnormalities of electrophysiological studies are found in approximately 
90% of established cases
7
. 
The hallmark of demyelinating polyneuropathies is a widespread increase in 
conduction time caused by impaired salutatory conduction. Therefore, NCS 
findings are characterized by significant slowing of conduction velocities (less than 
75% of the lower limit of normal) and distal latencies (greater than 130% of the 
upper limit of normal).The most common electrophysiological abnormalities in 
GBS include prolonged distal motor and F-wave latencies, absent or impersistent F 
waves, conduction block, reduction in distal CMAP amplitudes with or without 
temporal dispersion, and slowing of motor conduction velocities
36
.  
Electrodiagostic features are mild or absent in the early stages of GBS and 
lag behind the clinical evolution. Absent H-reflexes, delayed or absent F-waves, 
and low-amplitude or absent SNAPs in the upper extremity, combined with normal 
sural SNAPs, are changes supportive of the diagnosis in the first week of the 
illness
36
. Within the first 2 weeks, the most common findings are of mildly 
prolonged distal motor latencies and of conduction block 
35
. In cases with axonal 
degeneration, reduced CMAP and SNAP amplitudes are found, more markedly in 
18 
  
the lower extremities with conduction velocities and distal latencies being usually 
normal.  
Needle EMG initially shows decreased motor unit recruitment. 
Subsequently, if any amount of axonal degeneration occurs, fibrillation potentials 
appear 2–4 weeks after onset. Lumbosacral spinal MRI may demonstrate 
gadolinium enhancement of lumbar roots. 
DIFFERENTIAL DIAGNOSIS 
I. Acute neuropathies  
 Hepatic porphyrias 
 Critical illness neuropathy 
 Diphtheria 
 Toxins 
 Arsenic, thallium, organophosphates, lead 
 Neurotoxic fish and shellfish poisoning (ciguatoxin, tetrodotoxin, 
saxitoxin) 
 Buckthorn 
 Tick paralysis 
 Vasculitis 
 Inflammatory meningoradiculopathies 
 Lyme disease, cytomegalovirus lumbosacral radiculomyelopathy 
19 
  
II. Disorders of neuromuscular junction 
 Botulism, myasthenia gravis 
III. Myopathies 
 Hypokalemia, hypophosphatemia 
 Rhabdomyolysis 
 Polymyositis 
 Intensive care myopathy 
IV. Central nervous system disorders 
 Poliomyelitis 
 West Nile virus poliomyelitis 
 Rabies 
 Transverse myelitis 
 Acute brainstem infarct 
 spinal cord compression 
TREATMENT 
Treatment should be initiated as soon as possible after diagnosis. 2 weeks 
after the first motor symptom, it is not known whether immunotherapy is still 
effective
6
. If the patient has already reached the plateau stage, then treatment 
probably is no longer indicated, unless the patient has severe motor weakness. 
20 
  
Either high-dose intravenous immune globulin (IVIg) or plasmapheresis can 
be initiated, as they are equally effective for typical GBS. A combination of the 
two therapies is not significantly better than either alone. 
IVIg is often the initial therapy chosen because of its ease of administration 
and good safety record. Intravenous immunoglobulin (IvIg)given at 0.4 g/kg body 
weight/day for 5 days, is at least equally effective as plasma exchange
42,43
.There is 
some evidence that GBS autoantibodies are neutralized by anti-idiotypic antibodies 
present in IVIg preparations, perhaps accounting for the therapeutic effect. 
A course of plasmapheresis usually consists of 40–50 mL/kg plasma 
exchange (PE) 4–5 times over a week. Meta-analysis of randomized clinical trials 
indicates that treatment reduces the need for mechanical ventilation by nearly half 
(from 27% to 14% with PE) and increases the likelihood of full recovery at 1 year 
(from 55% to 68%)
38,39,40,41
. Significant improvement may occur toward the end of 
the first week of treatment, or may be delayed for several weeks. 
The lack of noticeable improvement following a course of IVIg or PE is not 
an indication to treat with the alternate treatment. 
About 10% of patients treated by plasma exchange will subsequently 
undergo a mild relapse between 5 and 42 days later, which may be treated by a 
further course of plasma exchange
44
. As with plasma exchange, IvIg-treated 
patients may deteriorate secondarily within 2 weeks of treatment
45
. 
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Neither oral steroids nor intravenous high-dose steroids have a place in 
treating the Guillain–Barré syndrome46. A randomized trial of oral prednisolone 
therapy suggested that steroids might increase the subsequent relapse rate
47
. 
Occasional patients with very mild forms of GBS, especially those who 
appear to have already reached a plateau when initially seen, may be managed 
conservatively without IVIg or PE. 
In the worsening phase of GBS, most patients require monitoring in a critical 
care setting, with particular attention to vital capacity, heart rhythm, blood 
pressure, nutrition, deep vein thrombosis prophylaxis, cardiovascular status, early 
consideration (after 2 weeks of intubation) of tracheotomy, and chest 
physiotherapy. Frequent turning and assiduous skin care are important, as are daily 
range-of-motion exercises to avoid joint contractures and daily reassurance as to 
the generally good outlook for recovery. 
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MATERIALS AND METHODS 
STUDY DESIGN 
Cross sectional study 
STUDY MATERIAL 
The study was conducted on 50 Guillain–Barré syndrome patients admitted 
in the Institute of Internal medicine, Rajiv Gandhi Government General Hospital, 
Chennai. 
INCLUSION CRITERIA 
 All adult patients who fulfilled standard diagnostic criteria for Guillain-
Barre syndrome as given by Asbury and Cornblath8,7,6,14 were included in the study. 
EXCLUSION CRITERIA 
1. Any patient admitted with asymmetrical weakness and preserved reflexes. 
2. Any patient with fever at the onset of symptoms. 
3. Any patient admitted with clinical or laboratory features of hypokalemic 
paralysis. 
4. Any patient in whom the weakness progressed for more than 4 weeks. 
5. Any patient admitted with features of upper motor neuron signs and symptoms. 
6. Any patient with a definite level of sensory loss or predominant sensory 
symptoms in the absence of muscle weakness. 
7. Any patient admitted with history of bite preceding the illness. 
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8. Any patient admitted with history of exposure to toxins. 
9. Patients with predominant/persistent bladder /bowel symptoms. 
10. Diagnosis of other causes of acute neuromuscular weakness (e.g., myasthenia 
gravis, botulism, poliomyelitis, toxic neuropathy). 
11. Abnormal CSF cytology suggesting carcinomatous invasion of the nerve roots 
12. Patients already intubated/ventilated while admitting in our hospital. 
13. Patients on steroid therapy. 
METHODOLOGY 
In all 50 patients, 
1. Detailed history including demographic factors, personal habits, preceding 
illnesses, co morbid illnesses, and clinical features was taken.  
2. Detailed neurological examination including higher mental functions, cranial 
nerves, motor system, sensory system and autonomic system was done 
everyday during hospitalization. 
Motor power was assessed according to Medical Research Council grading. 
Autonomic dysfunction was looked for in all these patients. History of postural 
giddiness (if ambulant), palpitation/tremors, excessive sweating/hypohydrosis, 
nausea, vomiting, constipation, diarrhoea, fecal/urinary incontinence, 
urinary/retention, dry mouth/dry eyes were specifically asked for. 
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Frequent blood pressure measurement was done in lying and sitting posture 
and if possible in standing posture to bring out orthostatic hypotension in ambulant 
patients. Resting pulse and pulse variability in lying and sitting posture and if 
possible in standing posture was done. Assessment of heart rate variability to deep 
breathing and valsalva was done in selected cases. Continuous BP, pulse and 
electrocardiographic (ECG) monitoring was done in intubated patients. 
Examination of eyes for pupillary abnormalities and dryness was done along with 
examination of skin and mouth. 
3. Bedside methods to detect the respiratory insufficiency were done in all patients 
at least 3 times daily, everyday during hospitalization, including breath-holding 
time, single breath count and chest expansion. Of which single breath count was 
widely used.  
Single breath count test (SBCT) has been used to evaluate the ventilatory 
status of patients with suspected neuromuscular compromise (e.g.,myasthenia 
gravis, Guillain–Barre syndrome, and botulism)55. 
The test is performed by having the patient count out loud after taking one 
deep breath. Most adults with normal ventilatory function are able to count to 50 in 
a single breath
54,55
. 
If the patient can count to "10" on one breath they likely have a forced vital 
capacity of about 1000 ml, if they can count to "25" then the vital capacity can be 
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estimated at about 2000 ml.In general a single breath count of <15 is consistent 
with significant impairment of the patient’s vital capacity54,55,56. 
4. Time to peak disability was assessed in all patients. Time to peak disability was 
defined as time to intubation (patients who underwent ventilation), or time to worst 
score on the MRC grading of muscle power (patients who did not undergo 
ventilation) from onset of neuropathic symptoms. 
5. Basic investigations like complete blood count, blood sugar and urea, serum 
creatinine and electrolytes, erythrocyte sedimentation rate, liver function tests, 
electrocardiogram and chest x-ray were done in all patients. 
6. Microbiological, Biochemical and cytological analysis of CSF was done in all 
patients. 
7. Serum cortisol level was analysed within 24 hours of admission in all patients. 
 8. Nerve conduction study was done in patients whomever it was possible. 
Nerve conduction study was conducted by using the machine RMS. Nerve 
conduction studies were done in both upper (ulnar and median nerve) and lower 
limbs (posterior tibial nerve and peroneal nerve).These evaluated F waves 
(absence, latency, chrono dispersion) in multiple motor nerves and H reflex 
(amplitude, latency) on stimulation of Posterior Tibial nerve. 
Motor nerve conduction studies included assessment of CMAP amplitude, 
distal motor latency (DML) and motor nerve conduction velocity (MNCV)along 
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with assessment for temporal dispersion and conduction block. Antidromic studies 
on median, ulnar, and sural nerve yielded sensory nerve conduction studies 
including sensory nerve action potential (SNAP) and sensory nerve conduction 
velocity (SNCV).  
Standard criteria, in comparison with standards for the particular laboratory, 
were applied to label a particular value as abnormal. Distal motor latency was 
prolonged if it was more than 150% of upper limit of normal. Motor conduction 
velocity was slowed if it was less than 70% of lower limit of normal and F wave 
latency was prolonged if more than 150% of upper limit of normal. Conduction 
block implied a 30% drop in CMAP amplitude on proximal stimulation as 
compared to distal stimulation, and temporal dispersion implied a 20% increase in 
CMAP dispersion on proximal stimulation, both these parameters indicating a 
proximal conduction block. Electrophysiological data were classified according to 
Hadden and colleagues
53
 definition as primary demyelinating, primary axonal, 
unexcitable, equivocal, or normal. 
These demographic, clinical, laboratory, electrodiagnostic tests data were 
recorded in a standard proforma. These data were analysed between patients who 
subsequently developed respiratory failure and those who did not develop 
respiratory failure.  
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Association of these demographic, clinical, laboratory, electrodiagnostic 
factors with respiratory failure was tested using Fisher’s exact test, χ2 test and 
Student t test.  
The study was approved by the institutional ethics committee of the hospital. 
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OBSERVATION AND RESULTS 
Fifty patients were included in our study. Demographic factors analysed 
were age, sex, co-morbid illnesses (DM, HT, respiratory illnesses), habits like 
smoking and alcoholism and antecedent events either preceding fever, upper 
respiratory illness, gastrointestinal illness, or other risk factors. 
AGE DISTRIBUTION:  The age distribution of 50 patients was as follows. 
                  TABLE 1: AGE DISTRIBUTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       
                                    FIGURE 1: GRAPH SHOWING AGE DISTRIBUTION 
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AGE (in years) 
AGE(in years) 
NO. OF 
PATIENTS 
PERCENTAGE  
11–20 2 4% 
21–30 9 18% 
31–40 14 28% 
41–50 12 24% 
51–60 9 18% 
61–70 3 6% 
71–80 1 2% 
Total 50  
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 All of them were between the age group of 15–75 years. The peak incidence 
was in the age group of 31 to 40 years and the median was 40 years. 
 Age distribution of patients with and without respiratory failure was as 
shown below in Table 2. 
                          TABLE 2: COMPARISON OF AGE AND RESPIRATORY FAILURE  
AGE 
(in years) 
RESPIRATORY FAILURE 
No. of Patients (%) 
NO RESPIRATORY 
FAILURE 
No. of Patients (%) 
<30 4(37%) 7(63%) 
30–60 21(60%) 14(40%) 
60–90 2(50%) 2(50%) 
 
 
 
 
 
 
 
                          FIGURE 2: GRAPH SHOWING COMPARISON OF AGE AND RESPIRATORY FAILURE 
Though 60% of persons in the age group 30–60 years developed respiratory 
failure, it did not reach statistical significance (χ2 test p=0.23) 
SEX DISTRIBUTION:  
Of the 50 patients, 31 were males and 19 were females. 
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TABLE 3: SEX DISTRIBUTION 
SEX NO. OF INDIVIDUALS PERCENTAGE 
Males 31 62% 
Females 19 38% 
               Among them 18 males and 9 females developed respiratory failure. 
TABLE 4: COMPARISON OF SEX AND RESPIRATORY FAILURE 
 
    
  
  
      χ2 test p=0.56 
 
   
   
 
               
            
                      FIGURE 3: GRAPH SHOWING COMPARISON OF SEX AND RESPIRATORY FAILURE 
When the influence of sex on the development of respiratory failure was 
analysed we found that sex did not influence the development of respiratory failure 
(χ2 test p=0.56) 
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RESPIRATORY 
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Males 18(58%) 13(42%) 
Females 9(48%) 10(52%) 
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CO–MORBID ILLNESSES AND HABITS 
Among the 50 patients, 12 were diabetics, 8 were hypertensives, 2 were 
asthmatics, 2 were coronary artery disease patients and 3 were treated pulmonary 
tuberculosis patients. 
TABLE 5: INCIDENCE OF CO MORBID ILLNESSES 
 
CO–MORBID ILLNESS NO. OF PATIENTS 
DM 12 
SHT 8 
Bronchial asthma 2 
CAD 2 
Treated PT 3 
 
Among the 12 diabetics, 9 developed respiratory failure and among the 38 
non-diabetics, 18 developed respiratory failure. 
 
TABLE 6: COMPARISON OF DIABETES MELLITUS AND RESPIRATORY FAILURE 
  
   
  
 
 
        χ2 test P= 0.11 
 
RESPIRATORY 
FAILURE 
No. of Patients 
NO RESPIRATORY 
FAILURE 
No. of patients 
DM 9 3 
No DM 18 20 
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                          FIGURE 4: GRAPH SHOWING COMPARISON OF DM AND RESPIRATORY FAILURE 
There were 8 hypertensive patients of which 6 patients and 21 among the 42 
non- hypertensive patients developed respiratory failure. 
                        TABLE 7: COMPARISON OF HYPERTENSION AND RESPIRATORY FAILURE 
 
RESPIRATORY 
FAILURE 
No. of patients 
NO RESPIRATORY 
FAILURE 
No. of patients 
HT 6 2 
No HT 21 21 
       Fischer’s exact test, p=0.26 
                    
      FIGURE 5: GRAPH SHOWING COMPARISON OF HT AND RESPIRATORY FAILURE 
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Among the 5 patients with preceding respiratory illness, 2 developed 
respiratory failure. 
            TABLE 8: COMPARISON OF RESPIRATORY ILLNESS AND RESPIRATORY FAILURE 
 
 
RESPIRATORY 
FAILURE 
No. of patients(%) 
NO RESPIRATORY 
FAILURE 
No. of patients(%) 
RESPIRATORY 
ILLNESS 
2(40%) 3(60%) 
NO 
RESPIRATORY 
ILLNESS 
25(56%) 20(44%) 
               Fischer’s exact test, p=0.65 
             
 
FIGURE 6: GRAPH SHOWING COMPARISON OF RESPIRATORY ILLNESS AND                       
RESPIRATORY FAILURE 
 
On analysing the co morbid illnesses it was found that co-morbid illnesses like 
diabetes (P=0.11), hypertension (P=0.26) or preceding respiratory illnesses 
(P=0.65) did not influence the development of respiratory failure. 
Among the 50 patients, there were 13 smokers and 6 alcoholics, of which 8 
smokers and 3 alcoholics developed respiratory failure. 
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TABLE 9:  COMPARISON OF SMOKING AND RESPIRATORY FAILURE 
 
 
RESPIRATORY 
FAILURE 
No. of Patients 
NO RESPIRATORY 
FAILURE 
No. of Patients 
SMOKING 8 5 
NO SMOKING 19 18 
               Fischer’s exact test, p= 0.75 
                        
        FIGURE 7: GRAPH SHOWING COMPARISON OF SMOKING AND RESPIRATORY FAILURE 
TABLE 10: COMPARISON OF ALCOHOLISM AND RESPIRATORY FAILURE 
  
RESPIRATORY 
FAILURE 
No. of Patients 
NO RESPIRATORY 
FAILURE 
No.of Patients 
ALCOHOLISM 3 3 
NO ALCOHOLISM 24 20 
                Fischer’s exact test, p= 1.00 
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                       FIGURE 8: GRAPH SHOWING COMPARISON OF ALCOHOLISM AND RESPIRATORY FAILURE 
 Hence it was found that smoking (p=0.75)/alcoholism (p=1.00) did not 
influence the development of respiratory failure. 
PRECEDING ILLNESSES 
Among the 50 patients 19 patients gave history of preceding symptoms and 
31 had no such history. 
TABLE 11:  INCIDENCE OF PRECEDING ILLNESS 
 
NO. OF PATIENTS PERCENTAGE 
PRECEDING ILLNESS 19 38% 
NO PRECEDING ILLNESS 31 62% 
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Among the 50 patients, 11 had preceding fever, 12 had preceding GIT 
illness, 9 had preceding respiratory illness, 2 persons had history of recent surgery, 
one was a hip replacement surgery and the other was following drainage of 
iliopsoas abscess. 
TABLE 12:  TYPES OF PRECEDING ILLNESS 
 
 
 
 
 
 
On analysing each preceding illness, the following results were obtained. 
TABLE 13: COMPARISON OF FEVER AND RESPIRATORY FAILURE 
                              
 
 
 
                            
          
Fischer’s exact test p=1.00 
PRECEDING ILLNESS NO OF PATIENTS 
FEVER 11 
GIT 12 
URI 9 
OTHERS 2 
 
RESPIRATORY 
FAILURE 
No. of patients 
NO RESPIRATORY 
FAILURE 
No of patients 
FEVER 6 5 
NO FEVER 21 18 
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              FIGURE 9: GRAPH SHOWING COMPARISON OF FEVER AND RESPIRATORY FAILURE 
TABLE 14:  COMPARISONOF GIT ILLNESS AND RESPIRATORY FAILURE 
 
RESPIRATORY 
FAILURE 
No. of patients 
NO RESPIRATORY 
FAILURE 
No. of patients 
GIT 5 7 
NO GIT 22 16 
              Fischer’s exact test p=0.50 
 
 
                     FIGURE 10: GRAPH SHOWING COMPARISON OF GIT ILLNESS AND RESPIRATORY FAILURE 
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                 TABLE 15: COMPARISON OF UPPER RESPIRATORY ILLNESS AND RESPIRATORY 
FAILURE 
 
 
RESPIRATORY 
FAILURE 
No. of patients 
NO RESPIRATORY 
FAILURE 
No. of patients 
URI 5 4 
NO URI 22 19 
              Fischer’s exact test p=1.00 
 
                 
         FIGURE 11: GRAPH SHOWING COMPARISON OF URI AND RESPIRATORY FAILURE 
 
Hence no statistically significant association was observed between the 
presence of preceding GIT illness (p=0.50), URI (p=1.00) or fever (p=1.00) and 
the development of respiratory failure. 
Clinical features analysed with respiratory failure were lowest limb muscle 
power, neck muscle weakness, bilateral facial weakness, autonomic dysfunction 
(unexplained blood pressure or heart rate fluctuations or significant bladder or 
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bowel dysfunction or arrythmias), bulbar weakness (dysarthria, dysphagia or 
impairment of the gag reflex) and time to peak disability. 
MUSCLE POWER 
All the patients had varying degrees of quadriparesis, lower limb weakness 
was more than the upper limb. Muscle power was assessed using MRC grading. 
On analysing the occurrence of respiratory failure among patients with 
various grades of muscle power by MRC grading the following observation was 
made. The least muscle power among the 4 limbs was taken for analysis. 
TABLE 16: INCIDENCE OF RESPIRATORY FAILURE IN VARIOUS MUSCLE POWER 
 
 
 
 
 
 
 
MUSCLE POWER  RESPIRATORY FAILURE 
(PERCENTAGE)  
0/5 60% 
1/5 57% 
2/5 57% 
3/5 56% 
4/5 40% 
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FIGURE 12.  PIE DIAGRAM SHOWING PERCENTAGE OF PATIENTS WHO DEVELOPED 
RESPIRATORY FAILURE WITH DIFFERENT MUSCLE POWER. 
 
Though 66% of patients with 0/5 muscle power developed respiratory 
failure, no significant association was found on statistical analysis (Fischer’s exact 
test p=1.000) 
NECK MUSCLE WEAKNESS 
Among the 50 patients 30 had neck muscle weakness of which 20 developed 
respiratory failure. Hence 67% with neck muscle weakness developed respiratory 
failure in contrast to 35% of those without neck muscle weakness. 
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            TABLE 17:  COMPARISON OF NECK MUSCLE WEAKNESS AND RESPIRATORY FAILURE 
 
 
RESPIRATORY 
FAILURE 
No. of patients(%) 
NO RESPIRATORY 
FAILURE 
No. of patients(%) 
NECK MUSCLE 
WEAKNESS 
20(67%) 10(33%) 
NO NECK MUSCLE 
WEAKNESS 
7(35%) 13(65%) 
         Fischer’s exact test p=0.043 
                           
FIGURE 13: GRAPH SHOWING COMPARISON OF NECK MUSCLE WEAKNESS AND 
RESPIRATORY FAILURE 
There was a significant association between the presence of neck muscle 
weakness and development of respiratory failure (p= 0.043) 
FACIAL PALSY, BULBAR PALSY, AUTONOMIC DYSFUNCTION 
Among the 50 patients, 14 had only facial weakness, 10 had only bulbar 
weakness and 10 had both bulbar and facial palsy. About 12 had autonomic 
dysfunction. The common manifestations of autonomic instability observed in our 
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study were fluctuating heart rate; episodic or sustained hypertension; orthostatic 
hypotension; episodic diaphoresis and tachy/bradyarrhythmias. 
 
TABLE 18: INCIDENCE OF FACIALPALSY, BULBAR PALSY AND AUTONOMIC  
DYSFUNCTION 
 
 
 
Among the patients who had facial weakness, bulbar weakness and 
autonomic instability, no of patients who required ventilator support subsequently 
is shown in the following table. 
TABLE19: INCIDENCE OF RESPIATORY FAILURE IN FACIAL PALSY, BULBAR PALSY AND 
AUTONOMIC DYSFUNCTION 
 
 
RESPIRATORY FAILURE 
NO RESPIRATORY 
FAILURE 
FACIAL 17 7 
BULBAR 17 3 
  AUTONOMIC 
DYSFUNCTION 
12 0 
         
       Among the 24 patients with facial weakness 71% developed respiratory failure 
                 
 
CLINICAL FEATURES NO OF PATIENTS 
FACIAL PALSY 24 
BULBAR PALSY 20 
AUTONOMIC DYSFUNCTION 12 
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                  TABLE 20:  COMPARISON OF FACIAL PALSY AND RESPIRATORY FAILURE 
                                          
 
 
 
                   
                 Fischer’s exact test, p = 0.026 
                   
    FIGURE 14: GRAPH SHOWING COMPARISON OF FACIAL PALSY AND RESPIRATORY FAILURE 
Among the 20 patients with bulbar palsy, 85% developed respiratory failure. 
TABLE 21: COMPARISON OF BULBAR PALSY AND RESPIRATORY FAILURE 
                 
Fischer’s exact test, p=0.0004 
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RESPIRATORY 
FAILURE 
No. of patients(%) 
NO  RESPIRATORY 
FAILURE 
No. of patients(%) 
FACIAL PALSY 17(71%) 7(29%) 
NO FACIAL PALSY 10(38%) 16(62%) 
 
RESPIRATORY FAILURE 
No. of patients(%) 
NO 
RESPIRATORY 
FAILURE 
No. of patients(%) 
BULBAR PALSY 17(85%) 3(15%) 
NOBULBAR 
PALSY 
10(33%) 20(67%) 
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FIGURE 15: GRAPH SHOWING COMPARISON OF BULBAR PALSY AND RESPIRATORY FAILURE 
   All of the 12 patients with autonomic dysfunction developed respiratory failure 
 
TABLE 22:  COMPARISON OF AUTONOMIC DYSFUNCTION AND RESPIRATORY FAILURE 
 
      Fischer’s exact test, p= 0.0002 
                   
FIGURE 16: GRAPH SHOWING COMPARISON OF AUTONOMIC DYSFUNCTION AND RESPIRATORY        
FAILURE 
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RESPIRATORY FAILURE 
No of patients(%) 
NO RESPIRATORY 
FAILURE 
No of patients(%) 
AUTONOMIC 
DYSFUNCTION 
12(100%) 0 
NO AUTONOMIC 
DYSFUNCTION 
15(39%) 23(61%) 
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       TABLE 23:   
 
RESPIRATORY 
FAILURE 
NO.OF 
PATIENTS(%) 
NO RESPIRATORY 
FAILURE 
NO.OF 
PATIENTS(%) 
P VALUE 
(FISCHER’S 
EXACT TEST) 
FACIAL PALSY 17(71%) 7(29%) 
0.026 
(significant) 
BULBAR 
PALSY 
17(85%) 3(15%) 
0.0004 
(extremely 
significant) 
AUTONOMIC 
DYSFUNCTION 
12(100%) 0 
0.0002 
(extremely 
significant) 
      p value : significant <0.05. 
Hence a highly significant association was observed between the presence of 
facial palsy, bulbar palsy, autonomic instability and the development of respiratory 
failure. 
TIME TO PEAK DISABILITY 
Time to peak disability is defined as time to intubation (patients who 
underwent ventilation), or time to worst score on MRC grading of muscle power 
(patients who did not undergo ventilation), from the onset of neuropathic 
symptoms
8
. 
Among the 50 patients 26 patients had time to peak disability as <7 days and 
24 patients had time to peak disability >7 days. 
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                  TABLE24. DISTRIBUTION OF TIME TO PEAK DISABILITY 
TIME TO PEAK 
DISABILITY 
NO OF PATIENTS PERCENTAGE  
1–7 DAYS 26 52%  
>7 DAYS 24 48%  
 
Among the patients with time to peak disability of <7 days, 73% developed 
respiratory failure in contrast to 33% of those with time to peak disability >7 days     
           TABLE 25: COMPARISON OF TIME TO PEAK DISABILITYAND RESPIRATORY FAILURE 
  
 
 
 
         
                 χ2 square test, p=0.0099 
                    
       FIGURE 17: GRAPH SHOWING COMPARISON OF TIME TO PEAK DISABILITY AND RESPIRATORY 
FAILURE 
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TIME TO PEAK 
DIABILITY 
RESPIRATORY 
FAILURE 
No. of patients(%) 
NO RESPIRATORY 
FAILURE 
No. of patients(%) 
1–7 DAYS 19(73%) 7(27%) 
>7 DAYS 16(33%) 8(67%) 
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Hence statistically significant association was observed between early time 
peak disability (<7 days) and the development of respiratory failure (p=0.0099) 
Transient sensory, bladder and bowel disturbances were observed in as few 
as 7 patients. Papilledema was observed in one patient. 1 patient was reactive for 
HIV. 
CSF PROTEIN AND SERUM CORTISOL 
The CSF protein level was distributed among the 50 patients as follows 
TABLE 26:  DISTRIBUTION OF CSF PROTEIN LEVEL 
 
 
 
 
 
 
 
 
 
The mean CSF protein level among those patients who developed 
respiratory failure was 117.39 mg/dl and among those who did not develop 
respiratory failure was 111.73 mg/dl 
 
CSF PROTEIN  
LEVEL(mg/dl) 
NO. OF PATIENTS 
91-100 6 
101-110 14 
111-120 16 
121-130 9 
131-140 5 
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 t test p= 0.11 
                 FIGURE 18: BAR DIAGRAM COMPARING CSF PROTEIN LEVEL AND RESPIRATORY FAILURE 
On analysing serum protein value and respiratory failure, no significant 
difference was observed in serum protein value among patients who developed 
respiratory failure and those who did not (p=0.11). 
The mean serum cortisol level was 30.63mcg/dl among those who developed 
respiratory failure and 20.83mcg/dl among those who did not develop respiratory 
failure. (Reference range of serum cortisol: 7–10 a.m.: 6.2–19.4 mcg/dl,4–8 
p.m.:2.3–11.9 mcg/dl ) 
   
    t test p= 0.00015 
FIGURE 19: BAR DIAGRAM COMPARING SERUM CORTISOL LEVEL AND RESPIRATORY FAILURE 
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Baseline serum cortisol level was significantly high in those who developed 
respiratory failure (p=0.00015). 
Mean serum cortisol level among patients with autonomic instability was 
33.23mcg/dl, and in those without autonomic instability was14.73 mcg/dl. 
 
                       t test p=0.004 
FIGURE 20: BAR DIAGRAM COMPARING SERUM CORTISOL LEVEL AND AUTONOMIC DYSFUNCTION. 
Hence mean serum cortisol level was significantly high in those with 
autonomic instability (P=0.004). 
NERVE CONDUCTION STUDY 
We were not able to do NCS in about 9 patients since we couldn’t mobilise 
them for NCS. The commonest finding observed was a radiculopathy, as evidenced 
by absent or impersistent F waves. Other common observations were prolonged 
distal motor latency, prolonged F wave latency, reduction in distal CMAP 
amplitudes with or without temporal dispersion, and slowing of motor conduction 
33.23 
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velocity. Electrophysiological data were classified according to Hadden and 
colleagues
53
 definition as primary demyelinating, primary axonal, unexcitable, 
equivocal, or normal.  
Accordingly, 21 had NCS features suggestive of demyelination, 14 had NCS 
features suggestive of axonal pathology and in 2 it was unexcitable/equivocal. 4 
patients had normal NCS features. 
TABLE 27: TYPES OF GBS BY NCS 
 
NCS NO. OF PATIENTS 
AIDP 21 
AMAN 12 
AMSAN 2 
NORMAL 4 
UNEXCITABLE/EQUIVOCAL 2 
TOTAL 41 
 
NCS pattern in patients who developed respiratory failure and in those who 
did not develop respiratory failure was as shown in the table below. 
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               TABLE 28: TYPES OF GBS (BY NCS) AND RESPIRATORY FAILURE 
  
NCS RESPIRATORY 
FAILURE 
NO RESPIRATORY 
FAILURE 
AIDP 10 11 
AMAN 5 7 
AMSAN 1 1 
NORMAL 1 3 
UNEXCITABLE/EQUIVOCAL 1 1 
TOTAL 18 23 
 
Since NCS was not done in 9 patients, we could not proceed with further 
statistical analysis. 
Respiratory function of each patient was assessed daily using SBCT. In our 
study, average SBC in patients who developed respiratory failure was below 16 on 
day 1 and there was a rapid decline in SBC compared to a gradual decline in SBC 
among patients who did not develop respiratory failure as shown below. 
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FIGURE 21: FIGURE SHOWING THE PATTERN OF DECLINE OF SBC IN RESPIRATORY FAILURE 
PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 22: FIGURE SHOWING THE PATTERN OF DECLINE OF SBC IN NON-RESPIRATORY 
FAILURE PATIENTS 
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DISCUSSION 
Neuromuscular respiratory failure is one of the major factors influencing 
morbidity and mortality in GBS. Successful management of GBS mandates 
anticipation of respiratory failure and timely intervention. 
Our study attempted to identify features that would predict respiratory 
failure. 50 patients were included in our study. Among them 27 patients developed 
respiratory failure. The proportion of patients developing respiratory failure and 
requiring assisted ventilation ranges from 12% in epidemiological series to 30% in 
hospital-based series
6,7
. In our study it was 54% which could because of our 
hospital being a tertiary care hospital. 
GBS occurs in either sex, with slight male preponderance, and at any age, 
occasionally including infancy. The mean age of onset is around 40
1
. 
In our study, age distribution among the 50 patients was such that all of them were 
between the age group 15–75 years. The peak incidence was in the age group of 
31–40 years and the median was 40 years. 
36% patients in the age group <30 years, 60% in the age group 30–60 years, 
50% in the age group 60–90 years developed respiratory failure. Hence none of the 
age groups showed increased susceptibility to respiratory failure. Hence age did 
not influence the development of respiratory failure (p value=0.23). 
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Of the 50 patients, 31(62%) were males and 19(38%) were females. Hence 
there was a male predominance. But patients with neither of the sex showed 
increased propensity to develop respiratory failure. Hence sex did not influence the 
development of respiratory failure(p value= 0.56). 
Hence age and sex did not influence the development of respiratory failure 
in our study. Similar observations were made by Nicholas D. Lawn et al
8
 and Uma 
Sundar et al
3
. 
Nicholas D. Lawn et al studied the influence of co-existing respiratory 
illnesses on the risk of developing respiratory failure and found an insignificant 
influence (p=0.28)
8
. In our study we analysed the influence of co-existing 
respiratory illness as well as diabetes and hypertension and we observed that the 
presence of these co-existing illnesses did not influence the development of 
respiratory failure (DM p=0.11,HT p=0.26, Respiratory illness p=0.65).  
We also analysed the effect of smoking and alcoholism on the development 
respiratory failure and we observed that neither of these influence the development 
of respiratory failure (smoking p=0.75, alcoholism p=1.00).
 
Among the 50 patients 19 (38%) patients gave history of preceding illnesses. 
They were either upper respiratory or gastrointestinal symptoms or fever and 2 
persons gave history of recent surgery- one was a hip replacement surgery and the 
other was drainage of iliopsoas abscess.  
55 
  
Winer et al. reported in 1988 that over half of Guillain–Barré syndrome 
patients experience symptoms of viral respiratory or gastrointestinal infections 
during the 1–3 weeks prior to the onset of neurological symptoms.  
But in our study 38% of patients had such preceding symptoms. 
Winer et al. also reported in 1988 that the neurological illness is preceded by 
symptoms of respiratory tract infection in approximately 40% and gastrointestinal 
infection in less than 20% in an English series. But in our patients preceding GIT 
(24% ) illness was observed to be more common than respiratory illness(18%). 
When each preceding illness was analysed with the development of 
respiratory failure, we observed that presence of a preceding illnesses did not 
influence the development of respiratory failure. [p = 0.50(GIT), p=1.00(URI), 
p=1.00(fever)]. This is in concordance with the observations made by Uma 
Sundaret al
3 
in their study done in Mumbai and by Marie-Christine Durand et al
4 
who analysed preceding GIT illness. 
Nicholas D. Lawn et al and Uma Sundar et al analysed in their study upper 
limb weakness with the development of respiratory failure and they observed that 
upper limb weakness did not influence the development of respiratory failure
8,3
. In 
contradiction, Marie-Christine Durand et al observed that the degree of upper limb 
weakness was more in ventilated patients but it did not reach statistical 
significance
4
. 
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In our study, all the patients had varying degrees of quadriparesis, lower 
limb weakness was more than the upper limb. Muscle power was assessed using 
MRC grading. 
The least muscle power of all 4 limbs was taken for analysis. 66% of 
patients with 0/5 power, 57% patients with 1/5 power, 57% patients with 2/5 
power, 56% with 3/5 power and 40% with 4/5 power developed respiratory failure. 
Though 66% of patients with 0/5 muscle power developed respiratory failure, the 
association did not reach statistical significance (p=1.00). 
Hence the degree of weakness of limbs did not influence the development of 
respiratory failure in our study similar to the above studies. 
Studies which analysed neck muscle weakness and respiratory failure in 
GBS gave contradictory results. Significant association (p value: 0.02) was 
observed in the study done by Marie-Christine Durand et al and Sharshar T.et al 
between neck muscle weakness and development of respiratory failure
4,51
. 
However Uma Sundar et al concluded in their study that neck muscle 
weakness did not predict requirement for mechanical ventilation
3
. 
In our study out of 30 patients with neck muscle weakness 20(67%) 
developed respiratory failure (p =0.043).Hence there was a significant association 
between the presence of neck muscle weakness and the development of respiratory 
failure.  
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Among 24 patients with facial weakness 71% developed respiratory failure. 
(p =0.026, considered statistically significant). Among the 20 patients with bulbar 
palsy, 85% developed respiratory failure (p=0.0004, considered extremely 
significant). All of the 12 patients with autonomic instability developed respiratory 
failure (p = 0.0002, considered extremely significant). 
Hence presence of facial palsy, bulbar palsy and autonomic dysfunction was 
significantly associated with the development of respiratory failure in our study. 
This is in concordance with the observations made by Nicholas D. Lawn et 
alin their study done in 1996 that progression to mechanical ventilation was highly 
likely to occur in those patients with bulbar dysfunction (p = 0.001), bilateral facial 
weakness(p =0.03), or dysautonomia (p = 0.009)
8
. 
Similar observations were also made by Sharshar T. et al.
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and Orlikowski 
D et al.
27
Uma Sundar et al differed from others stating that bifacial weakness did 
not influence development of respiratory failure in their study done in Mumbai , 
but they stated bulbar palsy and autonomic dysfunction as predictors of respiratory 
failure like  in other studies
3
. 
Time to peak disability was defined as time to intubation (patients who 
underwent ventilation), or time to worst score on MRC grading of muscle power 
(patients who did not undergo ventilation), from onset of neuropathic symptoms
8
. 
In our study 26 patients had time to peak disability as <7 days and among them 
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73% developed respiratory failure (p = 0.0099).Hence time to peak disability of <7 
days was significantly associated with the development of respiratory failure in our 
study. 
This is similar to the observations made by Nicholas D. Lawn et al in their 
study done in 1996, that the requirement for mechanical ventilation was associated 
with a shorter time to peak disability following the onset of neuropathic symptoms 
(p= 0.01)
8
 and also by Sharshar T.et al.at Raymond Poincaré Teaching Hospital, 
Garches, France.
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Elevated CSF protein level of 100-1000mg/dl without pleocytosis is the 
hallmark of GBS. The CSF is often normal when symptoms have been present for 
<48 hours. By the end of the first week level of protein is usually elevated
6
. 
 In our study, the mean CSF protein value among those patients who 
developed respiratory failure was 117.39mg/dl; not significantly different than 
those who did not develop respiratory failure111.73mg/dl (p=0.11). Hence CSF 
protein values did not influence the development of respiratory failure in our study. 
This is similar to the observations of by Marie-Christine Durand et al in France in 
1996 (p value 0.29)
4
. 
The mean serum cortisol level was significantly higher among patients with 
respiratory failure (30.63mcg/dl) than those who did not develop respiratory failure 
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(20.83mcg/dl); p= 0.00015 considered extremely significant. (Reference range of 
serum cortisol: 7–10 a.m.: 6.2–19.4 mcg/dl,4–8 p.m.:2.3–11.9 mcg/dl ) 
Hence high serum cortisol level was significantly associated with the 
development of respiratory failure in our study. This is similar to the observations 
made by Strauss J. et al at Medical Intensive Care Unit, Raymond Poincaré 
Teaching Hospital, Garches, France that the baseline plasma cortisol levels were 
significantly higher in patients, who developed respiratory failure at least 24 hrs 
later (28.5 +/− 12.1 ng/mL vs. 20.4 +/− 9.6 ng/mL; p = 0.003)5. 
In our study high serum cortisol level was observed among patients with 
autonomic dysfunction (mean: 33.23 mcg/dl) than those without autonomic 
dysfunction (mean:14.73 mcg/dl);p=0.04. This is in concordance with the 
observations made by Ahmad J. et al.in 1985 that in cases of Guillain–Barré 
syndrome with autonomic dysfunction the mean level of plasma cortisol was 27.25 
+/ 4.94 micrograms/100 ml  while in cases of Guillain–Barré syndrome without 
autonomic dysfunction it was 11.8 +/− 4.2 micrograms/100 ml49. 
Among the 50 patients, only 1 patient was reactive for HIV by ELISA test. 
Nerve conduction study was done in 41patients by using the machine RMS 
by standard method using surface electrodes. The commonest finding observed in 
both groups was a radiculopathy, as evidenced by absent or impersistent F waves. 
Other common observations were prolonged distal motor latency, reduction in 
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distal CMAP amplitudes with or without temporal dispersion, and slowing of 
motor conduction velocity. Electrophysiological data were classified according to 
Hadden and colleagues
53
 definition as primary demyelinating, primary axonal, 
unexcitable, equivocal, or normal. Majority has demyelination features on NCS 
(AIDP- 21 patients). 
Marie-Christine Durand et al stated that neurophysiological testing is 
helpful for assessing risk of respiratory failure, which is highest in patients with 
evidence of demyelination. He observed in  his  study  that demyelinating Guillain-
Barré syndrome was more common in patients who went on to be ventilated than 
in those who were not (85% vs. 51%, p=0·0003)
4
. But since we were not able to do 
NCS in 9 patients we couldn’t proceed with further statistical analysis. 
 Although there is insufficient evidence to recommend a specific method for 
monitoring respiratory function in patients with GBS, vital capacity is the most 
studied and used measurement in these patients. Chevrolet and Deleamont 
identified that a decline in VC of 50% from baseline was associated with 
subsequent ventilation within 36 hours and a drop in VC to an absolute value less 
than 1 L was associated with ventilation within 18 hours. Conversely, the serial VC 
measurements were stable and greater than 40 mL/kg in all patients who did not 
receive mechanical ventilation
57
. Due to lack of facilities we used serial 
measurement of single breath count instead of serial vital capacity measurement. 
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 Single breath count test (SBCT) has been used to evaluate the ventilatory 
status of patients with suspected neuromuscular compromise (e.g., myasthenia 
gravis, Guillain–Barre syndrome, and botulism) 55. In general a single breath count 
of <15 is consistent with significant impairment of the patient’s vital 
capacity
54,55,56
. Respiratory function was assessed in our patients with single breath 
count. Average SBC of <16 and a rapid decline of SBC was observed in patients 
who developed respiratory failure subsequently..  
Summary  
 
1. No significant difference was observed between patients who developed 
respiratory failure and those who did not with respect to age, sex, the presence of 
preceding illnesses, co-morbid illnesses, smoking/ alcoholism and the degree of 
limb weakness. 
2. Significant association was observed between rapid progression of disease 
(Time to peak disability of <7 days), presence of neck muscle weakness, facial 
palsy, bulbar palsy, autonomic instability and the development of respiratory 
failure.Hence presence of these factors either alone or in combination should alert 
the physicians that respiratory failure is likely to occur. 
 
 
 
62 
  
These factors may be used  
A) To decide on admissions in the Intensive care unit and preparation for 
elective intubation. 
B) To refer patients early from a primary health care centre. 
C) To educate patients to seek early medical attention. 
However the usage of the predictors of respiratory failure in clinical practice   is 
hindered by the fact that the clinical features in GBS do not occur sequentially, 
for example patients may develop autonomic instability after developing 
respiratory failure. However when present, before the development of 
respiratory failure, they are very useful. 
3. Results of cerebrospinal fluid analysis were similar in both groups. 
4. High baseline serum cortisol level was associated with the development of 
autonomic instability and respiratory failure. When facilities are available serum 
cortisol can be used as a valuable tool to anticipate the development of autonomic 
failure which is an important cause of death in GBS patients.  
Patients with high cortisol level may be promptly shifted to intensive care unit for 
want of continuous monitoring for the development of arrhythmias and the wide 
variation in blood pressure and pulse rate which are common in patients with 
autonomic dysfunction. 
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5. SBC of less than 16 and a rapid decline of SBC was observed in patients who 
developed respiratory failure. Such findings in a given patient should prompt 
referral to higher institution and preparation for an elective intubation. SBCT can 
be used to assess the respiratory function of GBS patients, in hospitals with lack of 
facilities to measure vital capacity 
Limitations of the study: 
1. Analysis of the contribution of electrophysiological factors in predicting 
progression to respiratory failure was limited by the amount of missing data. 
2. We could have got more impressive results if the sample size has been large. 
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CONCLUSION 
 Rapid progression of disease (Time to peak disability of <7 days), presence 
of neck muscle weakness, facial palsy, bulbar palsy, autonomic instability 
can predict the development of respiratory failure. 
 High baseline serum cortisol level can predict the development of autonomic 
instability and respiratory failure. 
 Single breath count of less than 16 and rapid decline of SBC can be used to 
predict respiratory failure. 
 These predictors can be useful in making decisions regarding admission in 
intensive care unit, preparation for elective intubation, prompt referral to a 
higher institute equipped with facilities for mechanical ventilation in 
Guillain-Barre Syndrome patients. 
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PROFORMA 
Name                             Age                    Sex                 In Patient No.   
Occupation                    Place                  Income    
Date of admission:                    Date of discharge/death: 
h/o GIT illness :  Y/N    
h/o URI : Y/N     
h/o Fever  : Y/N  
Others    :  Y/N  [h/o vaccination /trauma/surgeries/lymphoma/ drugs/SLE/ Post transplant] 
h/o DM    :  Y/N    
h/o HT  : Y/N 
h/o respiratory diseases  :Y/N [ COPD /BA/ others] 
h/o smoking  :  Y/N    
h/o alcoholism : Y/N 
Presenting complaints: 
Duration of symptoms on date of admission: 
h/o sensory disturbances: 
h/o bladder/ bowel disturbances: 
h/o altered sensorium/speech disturbances/memory disturbances: 
h/s/o cranial nerve involvement:                               
h/o ataxia: 
h/s/o autonomic dysfunction: 
a)Postural giddiness(if ambulant): 
b)Palpitation/tremors: 
c)Excessive sweating/hypohydrosis:    
d)Gastrointestinal or genitourinary symptoms: 
(nausea,vomiting,constipation,diarrhoea,fecal/urinaryincontinence,urinary retention):   
e) h/o dry mouth /dry eyes:    
Examination : 
Higher motor function abnormality Y/N 
Facial weakness:    Y/N           
Bulbar weakness:    Y/N          
Other cranial nerves: Y/N          
 
 
Motor system 
                                            DOA   to  DOPD  and    DOD 
Bulk  
Tone  
Power :  MRC  
UL Prox 
               Distal     
LL Prox 
               Distal 
Reflexes     Superficial : 
                  Deep tendon reflexes : 
Neck muscle weakness Y/N                                    
                                                             DOA   to   DOPD  
Single breath count  
Breath holding time 
Chest expansion  
Sensory involvement Y/N      
Autonomic system: 
    Dry Skin/excessive sweating: Y/N      
    Dry Eye: Y/N                                          Dry Mouth: Y/N      
    Blood pressure/pulse rate:       
                                         Supine     
                                         Sitting      
                                         Standing (if possible)   
                                         Arrhythmias: 
    Pupillary abnormalities: Y/N   
Fundus: 
Time to peak disability: 
Cardiovascular system:   
Respiratory system:                 
Abdomen: 
 
 
 
Complete blood count: 
Total count  
Differential Count  
ESR  
Hemoglobin  
Packed Cell Volume  
Platelet Count  
Renal function tests: 
Blood Sugar  
Blood Urea  
Serum Creatinine  
Serum Sodium  
Serum Potassium  
Liver function tests: 
Total Bilirubin  
SGOT  
SGPT  
SAP  
Total Proteins  
Serum Albumin  
 
X RAY chest: 
ECG  
CSF:   1) Protein 
          2) Sugar      
          3) Cell count   
          4) Cytology 
ELISA for HIV: 
Serum cortisol: 
Antinuclear antibody (if needed): 
NERVE CONDUCTION STUDY: 
  
 
 
 
 
 
DOA: Date of admission, DOPD: Date of peak disability, DOD: Date of discharge/death. 
DM HT OTHER FEVER GIT URI OTHERS
1 Durairani 25 F N N N N N N Y N N 8 Y 2 N N N N 108 12.4 Acellular AIDP
2 Mary 35 F N N Y(BA) N N N Y N N 12 N 3 N N N N 105 31 2-3 lymph AIDP
3
Rukkammal 50 F N N N N N N Y N N 15 Y
3
N N N N 123 14.05 Acellular
AMAN
4
Nandhagopal 68 M N N N N N N N Y Y 5 Y
4
Y Y Y Y 139 34.12 Acellular
AIDP
5
Vellaiyan 50 M Y N N Y Y N N N N 9 N
1
N N N N 99 14.3 Acellular
AMAN
6
Penecillaiah 38 M N N N N N N Y N N 10 Y
0
N Y Y Y 106
33.28
Occ 
lymphocytes
AIDP
7
Vidhyadaran 48 M N N N N N Y N N N 6 Y
3
N Y Y Y 96 28.61 Acellular
AMAN
8
Savithri 25 F N N N N N N Y Y N 14 N
4
N N N N 117 30.45 2-3 
lymphocytes
AIDP
9 Prabhu 33 M N N N N N Y N N N 5 N 2 Y Y N Y 119 13.83 Acellular
10
Pushpalatha 42 F N N Y(OLD PT) N N N N N N 3 Y
0
Y Y N Y 105
32.84
Occ 
lymphocytes
AMSAN
11 Perumal 60 M Y Y N Y Y N Y N N 4 N 3 N N N Y 118 28.2 Acellular AIDP
12 Christopher 51 M N N N N N Y N N N 5 Y 4 Y N N Y 126 35.32 Occ lymph AIDP
13
Basheer ahamed 35 M N N N N N N N Y N 8 Y
3
N Y N N 119
34.96
Acellular
AMAN
14 Murthy 15 M N N N N N N Y N Y 1 Y 4 Y N N Y 105 28.34 Acellular AIDP
15 Shanthi 45 F N N Y(CAD) N N N N N N 4 Y 3 Y Y N Y 128 30.03 Acellular AMAN
16
Suresh 39 M Y N Y(OLD PT) Y N N N N N 10 N
0
N N N N 119
14.03
Acellular
AIDP
17 Rathinam 65 M N Y N N N Y N Y N 15 Y 4 N Y N N 105 13.86 Acellular AMAN
18 nazeera 28 F N N N N N N Y Y N 6 Y 3 Y Y Y Y 99 36.05 Acellular AIDP
19
Balasubramaniu
m
74 M N N N Y N Y N N N 9 Y
1
N Y Y Y 134
35.19
Occ lymp
20 Raja 27 M N N N N N N N N N 8 N 1 N N N N 118 12.99 Acellular AMAN
21 Arunachalam 59 M Y Y N N N N N N N 7 Y 3 Y Y N Y 129 36.53 Acellular AIDP
22 Subramanium 48 M N N N N Y N N N N 9 Y 2 N N N Y 94 14.92 Occ lymp AIDP
23 Gopi 55 M Y N Y(CAD) Y N N N N N 4 Y 2 Y N N Y 121 31.7 Acellular AIDP
24 Vanmathy 38 F N N N N N Y Y Y N 4 N 3 N N N N 109 13.43 Occ lymp Normal
25 Venkatesh 30 M N N N N N N N N N 7 Y 4 N N N N 125 25.46 Acellular Normal
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26 Sumathy 45 F N N N N N Y N Y N 4 Y 3 N Y Y Y 130 33.98 Occ lymp AIDP
27 Balaji 34 M N N N N N N N N N 9 N 2 N N N N 112 13.07 Acellular AIDP
28 Venda 42 F Y N N N N N N Y N 8 Y 2 N Y Y Y 104 32.69 Acellular
29 Vinoth 19 M N N N N N Y Y N N 3 Y 3 Y N N N 92 31 Occ lymph AMAN
30
Punniyakotti 54 M Y Y Y(OLD PT) Y Y N N N N 6 Y
1
Y Y Y Y 137
33.42
Acellular
AIDP
31 Ramaniammal 55 F Y Y N N N N N N N 10 Y 2 Y N Y Y 112 33.96 Occ lymph
32 Devaki 28 F N N N N N N N N N 9 N 2 N N N N 116 27.95 Acellular AIDP
33 Kumar 24 M N N N N N N N N N 6 N 1 Y N N Y 120 13.33 Occ lymp AMSAN
34 Palani 54 M N N N Y N Y Y N N 15 Y 2 N N N N 112 14.23 Acellular AIDP
35
Mohammed 
yusuf
45 M N N N Y N N N N N 8 Y
3
Y N N Y 119
27.52
Acellular
AMAN
36 Sankari 36 F N N N N N N N N N 8 N 3 Y Y N Y 94 29.63 Occ lymp
37 Thomas 44 M Y Y N Y Y N N N N 4 Y 2 N Y N Y 132 31.59 Acellular AMAN
38 Balammal 35 F N N N N N N N N N 6 N 1 Y N N N 101 28 Occ lymp AMSAN
39 Vengaiyah 51 M Y N N Y N N N N N 7 N 2 Y N Y Y 114 35.86 Acellular
40
Sundari 35 F N N N N N N N N N 14 N
3
Y N N N 124
26.89
2-3 
lymphocytes
Normal
41
Thiruvengadam 48 M N N N N N Y N N N 6 Y
4
Y N Y Y 112
34.12
Acellular
AMAN
42 Kalaichelvan 39 M N N N Y Y N N N N 6 N 4 N N N N 109 12.99 Occ lymp AMAN
43 Sathyan 29 M N N N N N N N Y N 8 N 3 Y Y N Y 109 31.6 Acellular Normal
44
Jansi rani 33 F N N N N N N N N N 14 N
2
N N N Y 104
27.81
2-3 
lymphocytes
45 Vasantha 40 F N N N N N N N N N 5 N 4 Y N N N 121 12.08 Acellular AIDP
46 Murugan 37 M Y N N Y N N Y N N 6 Y 1 N Y N Y 140 30.03 Acellular
47 Abdul sherif 52 M Y Y N N N N N N N 10 Y 2 Y Y N N 113 33.9 Occ lymph AMSAN
48 Nagalakshmi 23 F N N Y(BA) N N Y N N N 7 N 3 Y N N N 105 12.94 Acellular AIDP
49 Kuppammal 38 F N N N N N N N N N 5 Y 2 N Y Y Y 118 27.51 Acellular
50 Kannaiyan 62 M N Y N Y N N N N N 9 Y 4 Y N N N 106 34.37 2-3 lymp AIDP
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